Literature DB >> 8880867

The role of p53 in cell cycle regulation.

P H Shaw1.   

Abstract

The tumor suppressor gene p53, implicated in diverse types of human tumors, functions both as a gene-specific transcription factor as well as a specific inhibitor of the transcription of certain genes. The two physiological outcomes of re-expression of wild type p53 in tumor cells, not expressing wild type p53, are G1 arrest and apoptosis. The mechanism of G1 arrest by p53 is much better documented than its ability to trigger apoptosis. P53 as a transcription factor induces the expression of p21WAF1/CIP1/Sdi1, an inhibitor of the cyclin dependent kinases (CDKs)2, 3, 4 and 6. Thus, a G1 arrest can result simply by the p53 induced expression of p21WAF1/CIP1/Sdi1. Amongst the other genes presently characterized to be regulated by p53 are BAX, a homologue of the BCL-2 gene. Bax does not trigger apoptosis, but simply accelerates the rate at which apoptosis proceeds54. P53 also down regulates the expression of cyclin A, providing a secondary break on cell cycle progression into the through the S phase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880867     DOI: 10.1016/S0344-0338(96)80088-4

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  32 in total

1.  Effect of eicosapentaenoic acid on the proliferation and incidence of apoptosis in the colorectal cell line HT29.

Authors:  R G Clarke; E K Lund; P Latham; A C Pinder; I T Johnson
Journal:  Lipids       Date:  1999-12       Impact factor: 1.880

2.  Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications.

Authors:  Seoung Wan Chae; Jin Hee Sohn; Dong-Hoon Kim; Yoon Jung Choi; Yong Lai Park; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo; Jun Ho Kim
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

3.  Renal Cell Carcinomas in Vinylidene Chloride-exposed Male B6C3F1 Mice Are Characterized by Oxidative Stress and TP53 Pathway Dysregulation.

Authors:  Schantel A Hayes; Arun R Pandiri; Thai-vu T Ton; Hue-Hua L Hong; Natasha P Clayton; Keith R Shockley; Shyamal D Peddada; Kevin Gerrish; Michael Wyde; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-12-17       Impact factor: 1.902

4.  Immunocytochemical accumulation of p53 in corticotroph adenomas: relationship with heat shock proteins and apoptosis.

Authors:  G Kontogeorgos; N Kapranos; E Thodou; D Sambaziotis; S Tsagarakis
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

Review 5.  How patients with an intact immune system develop head and neck cancer.

Authors:  Sarah Greene; Priya Patel; Clint T Allen
Journal:  Oral Oncol       Date:  2019-03-18       Impact factor: 5.337

6.  Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.

Authors:  Kelly M Thayer; Claudia Carcamo
Journal:  MOJ Proteom Bioinform       Date:  2020-02-05

7.  Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.

Authors:  Yixin He; Min Du; Yan Gao; Hongshuai Liu; Hongwei Wang; Xiaojun Wu; Zhengtao Wang
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

8.  Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.

Authors:  Dong-Hoon Kim
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

9.  Reduced P53 Staining in Actinic Keratosis is Associated with Squamous Cell Carcinoma: A Preliminary Study.

Authors:  Pimentel Dr Neto; Mma Alchorne; Ns Michalany; Mamm Abreu; Rc Borra
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

10.  Identification of Serological Biomarkers for Early Diagnosis of Lung Cancer Using a Protein Array-Based Approach.

Authors:  Jianbo Pan; Guang Song; Dunyan Chen; Yadong Li; Shuang Liu; Shaohui Hu; Christian Rosa; Daniel Eichinger; Ignacio Pino; Heng Zhu; Jiang Qian; Yi Huang
Journal:  Mol Cell Proteomics       Date:  2017-10-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.